Clinical ResearchRandomized Double-Blind Clinical Trial Comparing Clobetasol and Dexamethasone for the Topical Treatment of Symptomatic Oral Chronic Graft-Versus-Host Disease
-
Add time:08/23/2019 Source:sciencedirect.com
Patients who undergo allogeneic stem cell transplantation frequently develop an immunologic disease caused by the reactivation of the graft to the host tissues. This disease is called graft-versus-host disease (GVHD) and it is usually a systemic disorder. In a large proportion of cases, oral disorders that are related to a chronic phase of GVHD (cGVHD) occur, and their treatment involves the use of topical immunosuppressive drugs. Several medications have been studied for this purpose, but only a small number of clinical trials have been published. The present study is a randomized, double-blind clinical trial that compares topical clobetasol and dexamethasone for the treatment of symptomatic oral cGVHD. Patients were randomly assigned to treatment with clobetasol propionate .05% or dexamethasone .1 mg/mL for 28 days. In both arms, nystatin 100,000 IU/mL was administered with the corticosteroid. Oral lesions were evaluated by the modified oral mucositis rating scale (mOMRS) and symptoms were registered using a visual analogue scale. Thirty-five patients were recruited, and 32 patients were randomized into the study groups: 18 patients (56.3%) to the dexamethasone group and 14 patients (43.8%) to the clobetasol group. The use of clobetasol resulted in a significant reduction in mOMRS total score (P = .04) and in the score for ulcers (P = .03). In both groups, there was significant symptomatic improvement but the response was significantly greater in the clobetasol group (P = .02). In conclusion, clobetasol was significantly more effective than dexamethasone for the amelioration of symptoms and clinical aspects of oral lesions in cGVHD.
We also recommend Trading Suppliers and Manufacturers of Dexamethasone 17-propionate (cas 15423-89-9). Pls Click Website Link as below: cas 15423-89-9 suppliers
Prev:Leptin secretion in horses: Effects of dexamethasone, gender, and testosterone☆
Next:Enhancement of affinity to receptors in the esterified glucocorticoid, hydrocortisone 17-butyrate 21-propionate (HBP), in the rat liver) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enhancement of affinity to receptors in the esterified glucocorticoid, hydrocortisone 17-butyrate 21-propionate (HBP), in the rat liver08/24/2019
- Leptin secretion in horses: Effects of dexamethasone, gender, and testosterone☆08/22/2019
- Glucocorticoid dexamethasone down-regulates basal and vitamin D3 induced cathelicidin expression in human monocytes and bronchial epithelial cell line08/21/2019
- The effects of dexamethasone on cigarette smoke induced gene expression changes in COPD macrophages08/20/2019
- Radioimmunoassay for dexamethasone 17,21-dipropionate and its metabolites in plasma and urine after topical application08/19/2019
- Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids08/18/2019
- Dexamethasone reduces airway epithelial Cl- secretion by rapid non-genomic inhibition of KCNQ1, KCNN4 and KATP K+ channels08/17/2019
- Pre-clinical evaluation of novel mucoadhesive bilayer patches for local delivery of clobetasol-17-propionate to the oral mucosa08/16/2019
-
Health and Chemical more >
-
Related Products
- Dexamethasone 17,21-dipropionate
- Dexamethasone 21-(sodium hydrogen phosphate)
- Dexamethasone 21-phenylpropionate
- Dexamethasone 21-phosphate disodium salt
- Dexamethasone acetate monohydrate
- DEXAMETHASONE ISONICOTINATE
- Dexamethasone palmitate
- DEXAMETHASONE SODIUM SULFATE
- Dexamethasone trimethyl acetate
- DEXAMETHASONE VALERATE


